drugset / Trial / NCT02569710
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC) infection.
Timeline
- Start
- 2015-10-31
- Primary completion
- 2018-05-11
- Completion
- 2018-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAFOSBUVIR | Small molecule | 400 mg | — |
| Subject | ADAFOSBUVIR | Small molecule | 1200 mg | — |
| Subject | Odalasvir | Small molecule | 25 mg | — |
| Subject | Odalasvir | Small molecule | 50 mg | — |
| Subject | Simeprevir | Small molecule | 75 mg | — |
| Subject | Simeprevir | Small molecule | 150 mg | — |